ING, IAG and NEU: Three ASX stocks underperforming benchmark index

2 min read | February 16, 2024 04:45 PM AEDT | By Team Kalkine Media

Google News:

ING, IAG and NEU: Three ASX stocks underperforming benchmark index — Image source: Phongphan|Shutterstock

Recent News

Why REIT Income Remains a Key Focus on ASX 200

Defensive Strength ASX 200 Hidden in Infrastructure Assets

Can ASX 200 Banking Giants Shape Retirement Security?

Can ASX 200 Wealth Leaders Shape Australia’s Retirement Future?

Make Kalkine Media
My Trusted Source

As we navigate through the week, the benchmark index is currently showcasing a remarkable 0.69% upswing on 16 February 2024. This article delves into the market dynamics, focusing on the notable uptrend, while also shedding light on four ASX shares that have failed to ride this wave.

Inghams Group Ltd (ASX: ING)

In contrast to the overall market momentum, Inghams Group Ltd has witnessed a substantial 12.50% downturn in its share price, currently standing at AU$3.78. Despite doubling its half-year profits, investors seem reluctant, expressing concern over the management's outlook for the second half. This section dissects the intricacies of Inghams' market performance, examining both positive and negative indicators.

Insurance Australia Group Ltd (ASX: IAG)

Insurance Australia Group Ltd (IAG) is experiencing a 3.80% decrease in its share price, settling at AU$6.08. Despite reporting strong profit growth in the first half, IAG seems to have fallen short of investor expectations. Goldman Sachs provides a detailed analysis, outlining key aspects such as insurance profits, cash earnings, underlying margin, and reported margin. Evaluating these metrics offers insights into the discrepancy between projections and actual results.

Neuren Pharmaceuticals Ltd (ASX: NEU)

Neuren Pharmaceuticals Ltd faces a challenging afternoon trade, witnessing a significant 14.19% drop in its share price. This decline, with the stock hitting AU$19.78 before being paused from trade, stems from adverse developments involving its US partner Acadia Pharmaceuticals. A short seller's allegations regarding the Daybue drug licensed to Acadia have created a negative narrative around Neuren. Investors are reacting to reported "horror stories" associated with the drug.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.